These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
113 related articles for article (PubMed ID: 22166323)
41. New Zealand should introduce population screening for prostate cancer using PSA testing: yes. Smart R J Prim Health Care; 2009 Dec; 1(4):319-20. PubMed ID: 20690342 [No Abstract] [Full Text] [Related]
42. The distribution of serum prostate-specific antigen levels among American men: implications for prostate cancer prevalence and screening. Porter MP; Stanford JL; Lange PH Prostate; 2006 Jul; 66(10):1044-51. PubMed ID: 16598738 [TBL] [Abstract][Full Text] [Related]
43. Trends in prostate-specific antigen testing from 1995 through 2004. Farwell WR; Linder JA; Jha AK Arch Intern Med; 2007 Dec; 167(22):2497-502. PubMed ID: 18071173 [TBL] [Abstract][Full Text] [Related]
44. Why are a high overdiagnosis probability and a long lead time for prostate cancer screening so important? Barry MJ; Mulley AJ J Natl Cancer Inst; 2009 Mar; 101(6):362-3. PubMed ID: 19276451 [No Abstract] [Full Text] [Related]
45. Weighing the benefits and downsides of prostate-specific antigen screening. Pignone M Arch Intern Med; 2009 Sep; 169(17):1554-6. PubMed ID: 19786672 [No Abstract] [Full Text] [Related]
47. The case for prostate cancer screening. Andriole GL Semin Urol; 1993 May; 11(2):50-3. PubMed ID: 7689738 [TBL] [Abstract][Full Text] [Related]
48. Prostate-specific antigen tests and prostate cancer screening: an update for primary care physicians. Kell JS Can J Urol; 2010 Feb; 17 Suppl 1():18-25. PubMed ID: 20170597 [TBL] [Abstract][Full Text] [Related]
49. What can be concluded from the ERSPC and PLCO trial data? Studer UE; Collette L Urol Oncol; 2010; 28(6):668-9. PubMed ID: 21062648 [TBL] [Abstract][Full Text] [Related]
50. Is screening for prostate cancer the current gold standard?--"no". Kramer BS; Gohagan JK; Prorok PC Eur J Cancer; 1997 Mar; 33(3):348-53. PubMed ID: 9155515 [No Abstract] [Full Text] [Related]
51. Prostate-specific antigen levels in the United States: implications of various definitions for abnormal. Welch HG; Schwartz LM; Woloshin S J Natl Cancer Inst; 2005 Aug; 97(15):1132-7. PubMed ID: 16077071 [TBL] [Abstract][Full Text] [Related]
52. AUA issues a policy report on PSA monitoring. The American Urological Association. Scott Morey S Am Fam Physician; 2000 Aug; 62(4):883-4. PubMed ID: 10969861 [No Abstract] [Full Text] [Related]
53. An ecologic study of prostate-specific antigen screening and prostate cancer mortality in nine geographic areas of the United States. Shaw PA; Etzioni R; Zeliadt SB; Mariotto A; Karnofski K; Penson DF; Weiss NS; Feuer EJ Am J Epidemiol; 2004 Dec; 160(11):1059-69. PubMed ID: 15561985 [TBL] [Abstract][Full Text] [Related]
54. Observed effect of age and body mass index on total and complexed PSA: analysis from a National Screening Program. Walsh PC J Urol; 2005 Nov; 174(5):1825-6. PubMed ID: 16217298 [No Abstract] [Full Text] [Related]
56. Prostate specific antigen: a useful screening test? Concato J Cancer J; 2000 Apr; 6 Suppl 2():S188-92. PubMed ID: 10803835 [TBL] [Abstract][Full Text] [Related]
57. Cost-effectiveness of prostate specific antigen screening in the United States: extrapolating from the European study of screening for prostate cancer. Shteynshlyuger A; Andriole GL J Urol; 2011 Mar; 185(3):828-32. PubMed ID: 21239021 [TBL] [Abstract][Full Text] [Related]
58. The United States Preventive Services Task Force recommendation against prostate-specific antigen screening--point. Ablin RJ Cancer Epidemiol Biomarkers Prev; 2012 Mar; 21(3):391-4. PubMed ID: 22315362 [No Abstract] [Full Text] [Related]
59. Death knell for PSA screening? Mani H Natl Med J India; 2011; 24(6):380. PubMed ID: 22680272 [No Abstract] [Full Text] [Related]